Department of Pharmacy Practice, Nova Southeastern University, Fort Lauderdale, FL, USA.
Accountable Care Options LLC (Previously at Nova Southeastern College of Pharmacy), Boynton Beach, FL, USA.
J Pharm Pract. 2022 Jun;35(3):363-368. doi: 10.1177/0897190020977740. Epub 2020 Dec 11.
The Centers for Medicare and Medicaid Services (CMS) publishes quality measures to gauge performance in Accountable Care Organizations (ACOs). ACO-27 (Diabetes Mellitus: Hemoglobin A1c Poor Control) and ACO-41 (Diabetes: Eye Exam), are 2 components for the Diabetes Composite measure. ACO-42 focuses on Statin Therapy for the Prevention and Treatment of Cardiovascular (CV) Disease. There are limited studies regarding the pharmacist role in CV and Diabetes Management in the ACO primary care setting.
To evaluate the impact of pharmacist-led interventions on CV- and diabetes-related CMS quality measures within a primary care-based ACO.
This retrospective pre-post intervention study included 3 primary care-based ACO offices. Patients who met eligibility criteria for CMS quality measures ACO-27, -41 and -42 were included. Pharmacist interventions occurred in December 2018. The study co-primary outcomes were the percentage of patient meeting ACO-27/-41 (composite diabetes-related) and -42 (statin-related) CMS quality measures in the pre-intervention compared to the post-intervention phases.
Of 105 patients meeting study inclusion criteria, 77.1% were on statin therapy prior to intervention. After pharmacist intervention, the prevalence of patients on statin therapy increased to 80.0% (p = 0.083). All patients had a HbA1c less than 9% pre-intervention. Sixty-one (58.1%) patients had a documented dilated eye exam prior to intervention. Post-intervention, the prevalence of exams increased to 73.3% (p < 0.0005).
Pharmacists can assist primary care providers in the ACO setting meet CV- and diabetes-related CMS quality measures, demonstrating the value of the pharmacist in value-based health care settings.
医疗保险和医疗补助服务中心(CMS)发布质量措施,以衡量责任医疗组织(ACO)的绩效。ACO-27(糖尿病:糖化血红蛋白控制不佳)和 ACO-41(糖尿病:眼部检查)是糖尿病综合措施的两个组成部分。ACO-42 侧重于他汀类药物在心血管疾病(CV)预防和治疗中的应用。在 ACO 初级保健环境中,关于药师在 CV 和糖尿病管理中的作用的研究有限。
评估药师主导的干预措施对基于初级保健的 ACO 中与 CV 和糖尿病相关的 CMS 质量措施的影响。
这项回顾性的前后干预研究包括 3 个基于初级保健的 ACO 办公室。符合 CMS 质量措施 ACO-27、-41 和 -42 入选标准的患者被纳入研究。药师干预于 2018 年 12 月进行。本研究的主要结果是在干预前与干预后阶段,符合 CMS 质量措施 ACO-27/-41(综合糖尿病相关)和 -42(他汀类药物相关)的患者比例。
在符合研究纳入标准的 105 名患者中,77.1%在干预前接受他汀类药物治疗。经过药师干预后,接受他汀类药物治疗的患者比例增加到 80.0%(p = 0.083)。所有患者的糖化血红蛋白均低于 9%。在干预前,有 61 名(58.1%)患者有记录的散瞳眼部检查。干预后,检查的比例增加到 73.3%(p < 0.0005)。
药师可以协助初级保健提供者在 ACO 环境中满足与 CV 和糖尿病相关的 CMS 质量措施,证明了药师在基于价值的医疗保健环境中的价值。